CONTENTS

3  Welcome from the School of Biotechnology and Biomolecular Sciences (BABS)
4  Why do Honours in BABS?
6  BABS Indigenous Scholarship for Honours
8  How to apply for Honours in BABS for 2021
13 Research Projects: Genomics and Bioinformatics
21 Research Projects: Microbiology and Microbiomes
30 Research Projects: Molecular and Cell Biology
41 Approved External Honours Supervisors
42 Frequently Asked Questions
This handbook provides a guide for students considering undertaking Honours in the School of Biotechnology and Biomolecular Sciences (BABS) at UNSW Sydney during 2021. To be eligible, students must have maintained a credit average or above during their undergraduate program.

The BABS Honours program comprises undertaking a full-time research project supervised by a BABS researcher or approved external supervisor in an affiliated institution. Honours is an intensive year, but it is immensely rewarding intellectually. All research in BABS is aimed at advancing science to make a real difference in the world. By investigating and understanding life at the molecular and cellular level, our students help solve real-world challenges.

Research in BABS is aligned to three discipline areas:

- Genomics and Bioinformatics
- Microbiology and Microbiomes
- Molecular and Cell Biology

As you will see in this booklet, there is a wide scope of projects to interest Honours students, with research spanning human bacterial pathogens, functional genetics, gene regulation, systems biology, viruses, cancer, neurobiology, extremophiles, synthetic and structural biology and more.

The work spans from hypothesis-driven ‘blue sky’ research that advances human knowledge, to application-focused research that has potential medical and industrial benefits for society.

Our Honours students benefit greatly from world-class facilities that include the Ramaciotti Centre for Genomics, which houses next-generation genomic sequencing technology.

Apart from imparting skills in scientific research, another aim of the BABS Honours program is to equip students with skills in information technology, science communication and critical thinking, which will not only increase confidence but also make graduates more employable in an increasingly competitive workplace.

Our research community of staff and senior graduate students will do everything they can to ensure each student’s experience is as enjoyable and scientifically stimulating as possible.

We invite you to become a part of our research effort by undertaking Honours with us.
A key benefit of doing Honours in BABS is that it provides an active, hands-on learning experience in a scientific research environment. Students become part of a research team within a lab in the School, with supervisory oversight provided on an individual basis by an experienced academic. In addition, interaction with other experienced researchers within the group in an informal, relaxed atmosphere complements the formal part of the Honours program, of completing the predetermined research project and writing a thesis.

The Program is designed to provide advanced training and knowledge in one of the School's majors:

- Biotechnology
- Genetics
- Microbiology
- Molecular and Cell Biology

Honours may lead to postgraduate studies, but that is not the only purpose of the Program. Honours is also an opportunity for the student to reflect on their future career.

Honours graduates have the opportunity to develop greater competence and confidence in the practical skills and laboratory methods acquired during their undergraduate program, while developing key attributes sought by employers, including:

- Development of critical thinking skills
- Extensive use of a variety of information and communication technologies
- Familiarity with a range of computer software for oral and written presentations
- Training in online database manipulation and data analysis
- Collaboration in industrial research and commercialisation of science nationally and internationally

The higher level of such attributes are well recognised by employers and greatly increase the possibility of gaining employment in industry, agriculture, medical or research organisations.

Who is eligible for Honours?

Students must meet all requirements of their undergraduate degree (stages 1 to 3) before being considered eligible. Eligibility is contingent on academic merit, focused on performance in third-level Science subjects and overall WAM.

- Students with an average overall WAM of 65 or lower and/or an average of 65 or lower in third-level Science courses will usually not be accepted.
- Students who have achieved an average overall WAM of 65 or higher and an average of 65 or higher in third-level Science courses may be admitted if an approved supervisor is available.
- Admission to Honours requires the prior agreement of an approved BABS supervisor.

The major of a current BABS undergraduate student will normally determine their Honours enrolment category, but there is some flexibility depending on the student’s interests and availability of supervisor.

The selected research project of UNSW Medical Science students (3991 Program) and graduates from other Australian or overseas universities will determine the Honours category in which they enrol.
Components of the Honours Program

The major component of Honours is a research project carried out under the supervision of a BABS staff member or an approved external supervisor, culminating in a thesis. There are, however, other aspects of the program that make the Honours year in BABS especially attractive.

BABS Honours orientation course
Orientation for BABS Honours students comprises a series of tutorials and seminars held during the first week of the term. Attendance is compulsory. During this time, students will be fully occupied with workshop activities and will be discouraged from attempting research work.

Research plan seminar
You will develop and present a plan of your research for the year, in consultation with your supervisor: Why? How? When? This is a 10-minute seminar where other students and staff will attend your presentation. Your supervisor will provide you with feedback on your research plan after your seminar.

Literature review
The literature review is an important component of the continuous assessment for all Honours projects. It comprises a major assignment of approximately 3,000 words (not more than 4,000 words) on your project topic, selected in consultation with your project supervisor. The aims of this review are for students to become familiar with the UNSW library and all its resources, and to develop a critical approach in assessing published literature in the area relevant to your research project.

Final research seminar
Towards the end of their project, students will present a 15-20 minute seminar to the School on the outcomes of their research. This is worth 10% of the final mark.

Research project thesis
This major component of the Honours year accounts for 90% of the final mark. A written practice thesis is due for lodgement before the student’s final report will then be submitted as a final thesis. The final thesis mark is a combination of the written thesis, thesis interview, and overall lab aptitude throughout the Honours year.
BABS Indigenous Scholarship for Honours

The School of Biotechnology and Biomolecular Sciences is committed to improving Indigenous education opportunities and recognises that there may be impediments – financial or otherwise – that restrict Indigenous students from pursuing research avenues in science. As part of the university’s overall strategy, the School is dedicated to increasing the number of Indigenous students participating in higher education. We believe an increase in the engagement of non-Indigenous staff and students with Indigenous knowledge and culture will be of substantial benefit to the School at social, environmental, and educational levels.

Successful applicants will have the opportunity to undertake Honours in a School that fosters equity and diversity, with a real opportunity to make a difference to people’s lives through discoveries and sharing knowledge. The School is aware that Indigenous students bring their own rich tapestry of cultural experiences. Undertaking Honours in the School will afford students the opportunity to exchange ideas, learn from others, and both return to their communities and continue on a career path richer for the experience, and bearing tangible rewards in the form of improved research and teaching practices of substantial benefit to Australian science.

The School of BABS will offer a scholarship of $5,000, and work closely with Nura Gili, the university’s Indigenous Programs Unit, to assess applicants who identify as Aboriginal and/or Torres Strait Islander. Applicants will be assessed on academic merit and their contributions (past, present, and ongoing) to society and their community, that demonstrates their values and how a Scholarship would be of benefit to them, with a view to develop these further.

Details on the application process can be found on the UNSW Scholarships website: scholarships.unsw.edu.au/scholarships/id/1382/4391
Honours projects and supervisors

Information on available Honours supervisors and projects can be found in this booklet or on the BABS website. A total of five potential supervisors and projects must be selected and ranked in order of preference on the application form, bearing in mind that each supervisor has a limited capacity to take on new students. At least three choices must be from within BABS: a maximum of two choices may be external supervisors/projects. Applicants will be allocated to supervisors based on academic merit and available resources.

Once you have decided which supervisors you wish to contact for further discussion, email is the preferred method of contact. It is essential to spend some time with prospective supervisors to discuss the details of a project before submitting your preferences. In your email, please ensure that you:

(a) Identify which research project(s) you are interested in, and why
(b) Indicate which term you intend on commencing Honours (Term 1, 2 or 3)
(c) Advise your availability times for a face-to-face interview
(d) Attach a copy of your CV and academic transcript

Applicants in a UNSW embedded Honours program

*e.g. Bachelor of Biotechnology (Honours), Advanced Science (Honours)*

Complete the Category B ‘Intention to Undertake Honours’ form available on the Science Student Centre website: science.unsw.edu.au/honours-apply

Internal UNSW applicants and external applicants

Applying for 4500 Honours

1. Complete the Category A ‘Intention to Undertake Honours’ form available on the Science Student Centre website: science.unsw.edu.au/honours-apply
2. Apply for 4500 Science (Honours) on this website: applyonline.unsw.edu.au

The due date is 8 November 2020 for Term 1 commencement; TBA for Term 2 and 3 commencement.

International students need to follow the steps on the UNSW International Office ‘How to Apply’ page: international.unsw.edu.au/apply

(State that you are applying for Honours only).

Intention to Undertake Honours form due dates

For commencement in Term 1 2021:
8 November 2020

For commencement in Term 2 and 3 2021:
TBA

Honours inquiries

BABS Student Advisor
BABS School Office
Room 520, Biological Sciences Building D26
T 9385 8915
E j.zhao@unsw.edu.au

Please note that applications for Honours will be accepted only when five supervisor and project preferences are listed.
We are focused on enabling medical breakthroughs and clinical application with our access to cutting-edge computational biology. UNSW Biotechnology and Biomedical Sciences houses the Ramaciotti Centre for Genomics, the largest and most comprehensive genomics facility at any Australian University with an extensive suite of bioinformatics tools and next generation sequencing.

**RESEARCH PROJECTS**

**GENOMICS AND BIOINFORMATICS**

**CLUSTER STRENGTHS:**
- Gene Regulation
- Systems Biology
- Neurogenomics

Genomics and Bioinformatics is an invaluable hybrid of science, concerning the structure and function of genomes and the use of computational technology to capture and interpret biological data. While scientists previously focused on singular cells, the enormous development in bioinformatics over the last decade has enabled us to study cells on a mass scale.

We are focused on enabling medical breakthroughs and clinical application with our access to cutting-edge computational biology. UNSW Biotechnology and Biomedical Sciences houses the Ramaciotti Centre for Genomics, the largest and most comprehensive genomics facility at any Australian University with an extensive suite of bioinformatics tools and next generation sequencing.
RESEARCH FOCUS
Mitochondria as a model to study biochemical and bioenergetic link between genotype and phenotype; Genetics and behaviour of the Australian Dingo
Suitable for students who have majored in Genetics and/or Biochemistry

PROJECT 1
NUTRIGENOMICS AND THE MICROBIOME

Nutrigenomics is the scientific study of the interactions between nutrition and genes. Our recent studies have shown that diet interacts with mitochondrial DNA type to influence energy metabolism, development time and longevity in Drosophila flies. At this time, we do not know the underlying mechanisms involved. This project would involve raising flies and performing physiological and biochemical assays. Skills you will develop include: working with model organisms, media preparation, quantitative PCR and oxygen respirometry. This laboratory project would be conducted in the Drosophila insectary and biochemical lab at UNSW. It will inform our understanding of how diet can be manipulated to maximally effect survival and performance of an organism’s genotype.

Reference:

PROJECT 2
Y CHROMOSOME VARIATION IN THE AUSTRALIAN DINGO

We have finished the de novo sequencing and assembly of the genome from a Desert Dingo female and an Alpine dingo female. But, we have little information on the Y chromosome in dingoes. The goal of this project is to obtain Y chromosome information from two brothers of the dingoes we have de novo sequenced (see male below). Regions of the Y can then be compared with the same regions in domestic dogs and be included with the battery of markers used to determine dingo purity.

Reference:
❖ GCA_003254725.1, GCA_012295265.1

PROJECT 3
EXPRESSION DIFFERENCES BETWEEN DINGO ECOTYOE

Genetic evidence strongly suggests that there are at least two ecotypes of the Australian dingo. These are called “Alpine” and “Desert” types. We would like to determine whether there are any expression differences between these ecotypes (we have sequenced their genomes). This would be an RNA-seq study of the two dingo ecotypes followed by RT-PCR validation of a set of identified genes.

Reference:
**RESEARCH FOCUS**

The research in the Developmental Epigenomics lab aims to understand the contributions of the epigenome to embryonic development, evolution, and disease. We are particularly interested in how DNA methylation patterns are established, maintained and altered during those processes. Our interest in DNA methylation stems from the fact that this epigenetic mark can be stably propagated through cell division and that the presence or absence of DNA methylation correlates well with the activity of regulatory regions in both vertebrates and invertebrates.

**RESEARCH PROJECTS GENOMICS AND BIOINFORMATICS**

**Dr. Ozren Bogdanovic**

SENIOR RESEARCH FELLOW, FACULTY OF SCIENCE

Lab Head (Developmental Epigenomics), Garvan Institute of Medical Research

384 Victoria Street, Darlinghurst

T 9295 8340

E o.bogdanovic@unsw.edu.au

[https://babs.unsw.edu.au/ozren-bogdanovic](https://babs.unsw.edu.au/ozren-bogdanovic)

**DECODING THE BLUEBOTTLE: SYSTEM-LEVEL CHARACTERISATION OF THE INDO-PACIFIC MAN O’ WAR**

Siphonophores are predatory colonial animals from the phylum Cnidaria, which also includes corals, sea anemones, and jellyfish. Sometimes regarded as a metaorganism, each colony is formed by several different individual polyps also known as zooids. Unlike in other cnidarians, in siphonophores each zooid type has a specialised morphology and a specific role. In Australia, the siphonophore Indo-pacific man o’ war (Physalia utriculus), also known as the bluebottle, frequents our beaches in swarms every year resulting in thousands of painful stings.

The bluebottle, just like other siphonophores such as coral, is a colony of zooids. However, major differences exist between bluebottle zooids and those of coral, for example. Whereas the zooids in a coral colony are all functionally identical, in the bluebottle the zooids have specialised to the extent that they are no longer able to survive on their own. The relative yearly abundance of the bluebottle on Australian beaches thus allows for the opportunity to undertake systematic characterisation of its complex life cycle. The major goals of this research are to characterise the bluebottle at the molecular level through understanding its genome, transcriptome, and epigenome of functionally specialised zooids, and the toxin composition responsible for its painful sting.

We aim to reveal for the first time how complex colonial meta-organisms made of highly differentiated individuals have evolved, in a process that mirrors major evolutionary transitions towards integrated complexity.

Figure 1. Schematics of the genome sequencing and assembly strategy and diagram of functional genomics techniques that will be employed to characterise zooid-specific transcriptomes, DNA methylomes, and accessible chromatin.
We study how transcription factors control cell fate and how the breakdown of this process leads to disease. We apply this knowledge with the ultimate aim of developing the next generation of artificial transcription factors and to develop new therapeutic strategies for blood diseases. Currently, our collaborative research group includes 2 Postdoctoral Associates, 6 PhD students and 2 Honours students. Two Honours positions will be available for 2021.

**PROJECT 1**
**ENGINEERING THE NEXT GENERATION OF ARTIFICIAL TRANSCRIPTION FACTORS**

The ability to artificially regulate gene expression offers immense promise for the treatment of human diseases. In this project, we will apply knowledge of how natural transcription factors regulate their target genes to engineer a new generation of more potent artificial factors.

**PROJECT 2**
**REGULATING GLOBIN EXPRESSION: A POTENTIAL THERAPY FOR SICKLE CELL ANAEMIA AND THALASSAEMIA**

Sickle cell anaemia and thalassaemia are debilitating blood diseases that arise due to mutations in adult globin genes. In this project, we will investigate the networks involved in developmental regulation of globin gene expression, with an ultimate aim of reactivating the foetal globin genes.

**Techniques**
All projects offer the opportunity to learn a wide variety of molecular biology techniques, including Chromatin immunoprecipitation (ChIP), Western blotting, gel shifts, subcloning and bacterial transformation, site directed mutagenesis, CRISPR/Cas9 genome editing, PCR and real-time PCR, microarrays and next-generation technologies (RNA-seq and ChIP-seq), tissue culture, transient and stable transfections of mammalian cells, reporter gene assays and flow cytometry.

**Recent publications**
- ‘Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.’ Nature Genetics, 2018 50(4):498-503
- ‘Directing an artificial zinc finger protein to new targets by fusion to a non-DNA-binding domain’, Nucleic Acids Research, 2016, 44(7):3118-30
- ‘Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globin’, Nature Communications, 2015, 6:7085
Our research focuses on establishing new links between phenotype and genotype, particularly between rare and complex disease and underexplored regions of the genome, such as pseudogenes, repetitive elements, and those folding into non-canonical DNA structures or are transcribed into noncoding RNAs.

Four-stranded nucleic acids including G-quadruplexes and i-Motifs are emerging as biologically relevant DNA/RNA structures. Formation of these structures in cells have biological implications and aberrations that affect their stability can result in pathological conditions. We aim to develop novel biological and computational tools to study these structures. Currently, we have Honours projects available to investigate regulatory roles of these structures using a variety of molecular biology techniques, advanced microscopy, next generation sequencing, and bioinformatics analyses. Students will be encouraged to gain experiences in both wet and dry lab.

PROJECT 1
INVESTIGATING THE BIOLOGICAL RELEVANCE OF I-MOTIF RNA

Cytosine-rich sequences can form i-Motif structure. We have recently demonstrated that i-Motif DNA structures are formed in the nuclei of human cells and may have regulatory functions. In general, i-Motif RNA structures are less stable than their DNA counterparts and no regulatory function has been assigned to them. In this project, we will investigate sequences in the human transcriptome that can form i-Motif RNA with the ultimate goal of understanding their regulatory roles.

PROJECT 2
DETERMINING THE RELATIONSHIP BETWEEN STRUCTURE AND FUNCTION OF TERRA

Telomeric repeat-containing RNA (TERRA) is a long non-coding RNA transcribed from human telomeric regions. TERRA involves in regulation and protection of chromosome ends and it induces a genome-wide alteration of gene expression in some type of cancer cells. Interestingly, TERRA can fold into a G-quadruplex structure. In this project, we will examine to what extent the formation of a G-quadruplex structure by TERRA is important for its function, with an emphasize on its potential role in the cancer development.

References:
❖ Zeraati M; Langley DB; Schofield P; Moye AL; Rouet R; Hughes WE; Bryan TM; Dinger ME*; Christ D*, 2018, ‘I-motif DNA structures are formed in the nuclei of human cells’, Nature Chemistry, vol. 10, pp. 631 - 637
❖ Clark MB; Mercer TR; Bussotti G; Leonardi T; Haynes KR; Crawford J; Brunck ME; Cao KA L; Thomas GP; Chen WY; Taft RJ; Nielsen LK; Enright AJ; Mattick JS; Dinger ME, 2015, ‘Quantitative gene profiling of long noncoding RNAs with targeted RNA sequencing’, Nature Methods, vol. 12, pp. 339 - 342
Our research focuses on studying transcriptome in the human brain and peripheral tissues using short- and long-read RNA sequencing. We are particularly interested in the role of circular RNAs (circRNAs), linear RNA splicing patterns and RNA modifications in regulation of molecular physiology of human tissues. Moreover, we aim at identifying RNA transcripts which can serve as biomarkers of early onset of human complex diseases including neurological disorders and cancer.

**PROJECT 1**
**INVESTIGATION OF TISSUE-SPECIFIC EXPRESSION OF CIRCULAR RNAs IN THREE MAMMALIAN SPECIES**

Recent advances in RNA sequencing technology allowed discovery of a new RNA species, circular RNAs (circRNAs; Figure 1). CircRNAs have been identified as a naturally occurring family of widespread and diverse endogenous noncoding RNAs that may regulate gene expression in mammals (Huang et al. 2017) and are perturbed as a result of neurodegeneration and cancer (Chen et al. 2016). They are unusually stable RNA molecules with cell type- or developmental stage-specific expression patterns. Thousands of circRNAs have been identified, with the majority of studies sequencing brain and disease tissue samples. There is however an urgent need to understand circRNA expression patterns and their properties in peripheral, non-brain, healthy tissues not only in humans but also in other mammalian species used as experimental models for investigation of complex diseases. To address this challenge the project aims focuses on investigation of circular transcriptome landscapes in ten different peripheral tissue types derived from three mammalian species, including human, macaque and mouse.

![Figure 1: The formation of linear mRNAs and circular RNAs through canonical splicing and backsplicing, respectively. The mechanism of backsplicing leads to covalent linkage of the downstream 3'-end of a pre-mRNA sequence to an upstream 5'-end of the pre-mRNA strand. This process leads to generation of a backspliced junction (BSJ), denoted by the black line in circular isoforms, which is a unique feature of circRNAs. Linear mRNAs are formed through the canonical splicing process whereby introns are excised from the pre-mRNA strand, forming exonic isoforms of linear mRNA with no BSJ (adapted from Curry-Hyde et al. 2019).](image)
Nanopore direct RNA sequencing technology has just only recently become available for genomic research. This revolutionary technique allows to investigate human transcriptome, including mitochondrial one, at an unprecedented resolution. Nanopore RNA sequencing differs from Illumina short-read RNA sequencing technology platform in that native RNA nucleotides, rather than copied DNA nucleotides, are identified as they thread through and touch a nanoscale sensor. Nanopore direct RNA sequencing shares the core features of nanopore DNA sequencing where a processive helicase motor regulates movement of a bound polynucleotide driven through a protein pore by an applied voltage. As the polynucleotide advances through the nanopore in single-nucleotide steps, ionic current impedance reports on the structure and dynamics of nucleotides in the channel as a function of time. This continuous ionic current series is converted into nucleotide sequence using a neural network algorithm trained with known RNA molecules (Figure 2).

Breast cancer is the leading cause of cancer-related death in women, worldwide. It is a heterogeneous malignancy with regard to molecular alterations, cellular composition, and clinical outcome, both between tumour subtypes and within a single tumour. Invasive ductal carcinoma (IDC) is the most common type of breast cancer as about 80% of all breast cancers are invasive ductal carcinomas. Despite numerous studies investigating gene expression profiles in IDC almost nothing is known about aberration of alternative splicing and epigenetic modifications of mRNAs specifically expressed in this malignancy. Therefore, the aim of this project is to apply nanopore direct RNA sequencing technique for discovery of novel transcriptional isoforms and RNA modification patterns in IDC.

References:

This is a Bioinformatics project. The aim of this project is to investigate the genomic locations of bleomycin cleavage in human cells.

The glycopeptide antibiotic, bleomycin, is used as a cancer chemotherapeutic agent to treat testicular cancer, squamous cell carcinoma, and Hodgkin’s lymphoma. Its mechanism of action is thought to involve DNA damage and DNA cleavage. Both double-strand and single-strand breaks are formed by bleomycin although double-strand breaks are thought to be most important for the anti-tumour activity of bleomycin.

In our previous studies [1-3], the genome-wide pattern of DNA cleavage at transcription start sites (TSSs) for the anti-tumour drug, bleomycin, was examined in human HeLa cells using next-generation DNA sequencing. It was found that actively transcribed genes were preferentially cleaved compared with non-transcribed genes. The bleomycin cleavage pattern at highly transcribed gene TSSs was greatly enhanced compared with purified DNA and non-transcribed gene TSSs. The pattern of bleomycin enhanced cleavage had peaks that were approximately 200 bp apart, and this indicated that bleomycin was identifying the presence of phased nucleosomes at TSSs. Hence bleomycin can be utilised to detect chromatin structures that are present at actively transcribed genes.

Hence bleomycin can be used as a probe of chromatin structure. In this project, it is proposed that other genomic features of chromatin (other than TSSs) are investigated. These features include splice sites, promoter sites, transcription stop sites, repeated sequences, etc. A similar pipeline to the TSS procedure will be used to assess these genomic features of human cellular genomic DNA.

References:
Our research is focused on the discovery of new human disease genes, and analysis of the clinical-, RNA transcript-, protein- and tissue-level impacts of disease-causing mutations within known and emerging human disease genes. We use this information to increase genetic diagnosis rates for affected individuals and their families, to advance our understanding of the clinical characteristics, natural history, and underlying pathogenesis of the genetic disorders we study, and to develop potential new therapies for these disorders.

Our main area of research interest is the discovery of new genes responsible for congenital muscular dystrophies (CMDs) and congenital myopathies (CMYOs). CMDs and CMYOs are primary genetic muscle disorders affecting babies and young children. They cause significant muscle weakness and physical disability and can result in early death. Around half of all children with CMD/CMYO still do not have genetic diagnosis. In many cases this is because the causative gene has not yet been identified. In addition, there are no available treatments to prevent, halt, or slow the progression of most forms of CMD/CMYO – even when the genetic basis is known.

TEAM AREA OF INTEREST 1: CONGENITAL MYOPATHY/ DYSTROPHY DISEASE GENE DISCOVERY USING STATE-OF-THE-ART GENOMIC SEQUENCING TECHNOLOGIES.

Our team offers projects that involve in-depth analysis of whole exome and whole genome massively parallel sequencing data from children with early-onset muscle disorders (e.g. CMD and CMYO) who do not currently have a genetic diagnosis despite extensive investigation. Patient sequencing data is analysed via a web-based portal in parallel with sequencing data from both unaffected parents (“trio analysis”) in order to increase the chance of identifying the causative mutation(s). If potentially pathogenic variants in possible new disease genes are identified, students draw on existing literature and database-accessible information to determine the biological plausibility of the gene as a new muscle disease gene (e.g. Is the gene expressed in muscle? Does the gene encode a protein involved in a pathway known to be altered in other muscle diseases?). Students will also determine the likely pathogenicity of their variants of interest using (1) in silico-based, RNA-seq and protein-based analytical techniques, and (2) by finding additional patients with mutations within the same gene via our well-established collaborator network and clinical ‘matchmaking’ programs. Depending on the interests of the student and the discoveries made, these projects may extend to involve comprehensive clinical description of newly-identified disorders, cell-based functional assays, and/or animal studies undertaken in collaboration with other teams.

Our team also offers projects that involve analysis of control and disease striated (cardiac and skeletal) muscle transcriptomic (RNA-seq) data to determine (1) normal patterns of splicing and isoform/exon usage at various stages of development, as well as (2) abnormal splicing patterns and/or abnormal isoform/exon usage caused by patient mutations. This area of research is greatly expanding our understanding of normal muscle isoform biology and genetic muscle disease pathogenesis. Data generated by these projects will also be used to inform the development of muscle-disease-focussed exon-skipping drug therapies aimed at “skipping” disease-causing mutations but retaining critical (highly used) neighbouring exons.

TEAM AREA OF INTEREST 2: ADVANCING OUR UNDERSTANDING OF NORMAL MUSCLE ISOFORM BIOLOGY AND MUSCLE DISEASE PATHOGENESIS USING STATE-OF-THE-ART TRANSCRIPTOMIC (RNA-SEQ) TECHNOLOGIES.

Our team also offers projects that involve control and disease striated (cardiac and skeletal) muscle transcriptomic (RNA-seq) data to determine (1) normal patterns of splicing and isoform/exon usage at various stages of development, as well as (2) abnormal splicing patterns and/or abnormal isoform/exon usage caused by patient mutations. This area of research is greatly expanding our understanding of normal muscle isoform biology and genetic muscle disease pathogenesis. Data generated by these projects will also be used to inform the development of muscle-disease-focussed exon-skipping drug therapies aimed at “skipping” disease-causing mutations but retaining critical (highly used) neighbouring exons.

TEAM AREA OF INTEREST 3: ADVANCING OUR UNDERSTANDING OF DISORDERS CAUSED BY TTN (TITIN) MUTATIONS (“THE TITINOPATHIES”)

This series of projects involves the use of state-of-the-art genomic and transcriptomic technologies, as well as detailed clinical phenotyping and natural history analyses, to advance our understanding of “The titinopathies”. These are an important emerging group of cardiac and skeletal muscles disorders caused by mutations in one of the largest genes in nature – TTN (titin). This gene was much too large to be comprehensively sequenced on a routine diagnostic basis prior to the advent of massively parallel sequencing technology (MPS). MPS-facilitated diagnostic sequencing of TTN has revealed that mutations in this gene cause a number of important skeletal muscle and cardiac disorders. In fact, it now appears that congenital titinopathy, the most severe titinopathy, is the most common congenital myopathy (CMYO) worldwide. In addition, dominant TTN truncating mutations are the most common genetic cause of adult-onset dilated cardiomyopathy. In collaboration with an international army of clinicians and researchers, we have established a large cohort of titinopathy patients, 30 of which were described in a recent high impact publication (Oates et al, Congenital titinopathy: comprehensive characterisation and pathogenic insights. Ann Neurol, 2018). The goal of this area of research is to broaden our understanding of the clinical, muscle pathology and imaging features, and the genetic basis of this important group of disorders. These projects would suit a medical student, or a science student with an interest in human genetic diseases. The focus can be tailored to the specific interests of the student.
Dr Richard Edwards
SENIOR LECTURER
Room 2110, Level 2 East
Bioscience South Building E26
T 9385 0490
E richard.edwards@unsw.edu.au
babs.unsw.edu.au/richard-edwards

RESEARCH FOCUS
Eukaryotic evolutionary genomics using long-read sequencing; applying biological sequence analysis and molecular evolution to study the molecular basis of protein-protein interactions.

Suitable for students who have majored in Biochemistry, Molecular Biology, Microbiology or Genetics. Would suit students with some programming experience and interests in evolution/genomics, or vice versa.

PROJECT 1
EUKARYOTIC EVOLUTIONARY GENOMICS

We are using the latest generation of sequencing, assembly and scaffolding technologies (10x Chromium “linked reads”, PacBio, Oxford Nanopore, HiC) to assemble multiple species including venomous snakes, the cane toad, marsupials, dog breeds, and Australian flora. Multiple genomics-related projects are available through as range of species through various collaborations and consortia, including Oz Mammals Genomics, Genomics of Australian Plants, and Australian Amphibian and Reptile Genomics. Projects include annotating genomes and/or specific gene families, developing bioinformatics tools/workflows for assessing and tidying genome assemblies, and identifying/characterising ultraconserved elements. Whilst we are a bioinformatics lab, we collaborate directly with a lot of field and lab biologists and so there are also opportunities to get involved in aspects of the data collection. Collaborative projects with other BABS academics are also possible.

PROJECT 2
DIPLOID YEAST GENOME ASSEMBLY

The latest generation of long-read sequencing has revolutionised microbial genomics. We are using Oxford Nanopore Technologies (ONT) and PacBio single molecule real-time (SMRT) long-reads to sequence and assemble a number of yeast strains, including many dipoilds. A number of student projects are available in collaboration with BABS and our industry partner (Microbiogen Pty Ltd), including: improving whole genome assembly workflows; completing and annotating genomes; comparative genomics to identify molecular mechanisms for novel biological functions.

PROJECT 3
USING CROSS-LINKING MASS SPECTROMETRY FOR PROTEIN INTERACTION PREDICTION

Many protein-protein interactions are mediated by short protein sequences called Short Linear Motifs (SLiMs). Traditionally, large-scale experimental data has struggled to capture these interactions, as they are often transient and low affinity. Cross-linking mass-spectrometry (XL-MS) offers the potential to capture interactions and important regions of each protein. This project will apply state-of-the-art SLiM prediction tools developed in our lab to new yeast XL-MS data and published human datasets to explore the potential of these data for interaction motif prediction.

References:
❖ Edwards RJ et al. (2018) Pseudodiploid pseudo-long-read whole genome sequencing and assembly of Pseudonaja textilis (eastern brown snake) and Notechis scutatus (mainland tiger snake) [version 1; not peer reviewed], F1000Research 7:753 (poster).
❖ Field MA et al. (2020): Canfam_GSD: De novo chromosome-length genome assembly of the German Shepherd Dog (Canis lupus familiaris) using a combination of long reads, optical mapping, and Hi-C. GigaScience 9(4):giaa027.
Big data and artificial intelligence – driving personalised medicine of the future

Big data has become a ubiquitous watchword of biomedical innovation advocating deployment of advanced data-driven artificial intelligence techniques and systems thinking to revolutionise biomedical research and practice. I lead AI-empowered Biomedicine Laboratory where we cutting-edge innovative machine-learning and network science methodologies to leverage large-scale molecular and clinical data to find hidden structures within them; account for complex interactions among the measurements, integrate heterogeneous data and make accurate predictions in different biomedical. Honours students will be involved in cutting-edge multidisciplinary and collaborative ongoing research projects and encouraged to publish their research outcome. My research program focuses on three topical areas of .

1 Minimally invasive biomarker discovery for personalised medicine and precision therapy

Recent advances in high-throughput technologies have provided a wealth of genomics, transcriptomics, and proteomics data to decipher disease mechanisms in a holistic and integrative manner. Such a plethora of -omics data has opened new avenues for translational medical research and has particularly facilitated the discovery of novel biomarkers for complex diseases such as cancers. My research lab – in close collaboration with experimentalists, clinicians, and oncologists – is adopting an innovative multi-disciplinary approach to tackle one of the biggest challenges of personalised cancer medicine, that is to identify robust and reproducible biomarkers in a minimally invasive way. We are integrating multiple data sources, network and temporal information using advanced machine learning and deep learning approaches to better understand the molecular complexity underpinning pathogenesis and to identify novel, precise and reproducible blood-based biomarkers for disease early-detection, diagnosis, prognosis and drug responses paving the way for personalised medicine.

2 Single-cell sequencing data analysis and integration

Cellular heterogeneity is one of the main clinical drivers of the current inefficiency in treating cancer and other complex diseases as molecular-based prescriptions or personalised medicine have often relied on bulk profiling of cell populations, masking intercellular variations that are functionally and clinically important. In recent years, however, there has been an increasing effort in shifting the focus from bulk to single-cell profiling. Single-cell sequencing will have a major global impact on the precision medicine through detecting rare disease-associated cells and identifying cell-type-specific biomarkers and therapeutic targets. Single cells, however, make ‘big data’, provoking substantial analytical challenges to decipher underlying biological and clinical insights. Hence, there is an emerging demand for scalable yet accurate analysis pipelines for rapidly increasing single-cell sequencing data and my research program is focused (during the last 18 months) to contribute to this significant field.

3 Computational drug repositioning and network pharmacology

Repositioning existing drugs for new indications is an innovative drug development strategy offering the possibility of reduced cost, time and risk as several phases of de-novo drug discovery can be bypassed for repositioning candidates. Biopharmaceutical companies have recognised advantages of repositioning, and investment in the area is dramatically increasing. With the rapid advancement of high-throughput technologies and the explosion of various biological and medical data, computational drug repositioning has become an increasingly powerful approach to systematically identify potential repositioning candidates. My lab is one of the few across Australia, advancing the field of computational drug repositioning. We are developing computational tools and databases which integrate massive amounts of biological, pharmacological and biomedical information related to compounds into advanced machine learning or network-based models to predict accurate repositioning candidates.

Selected References:

- Vafaee F, Diakos C; Kirschner M; Reid G; Michael M; Horvath LISA; Alinejad-Rokny H; Cheng ZJ; Kuncic Z; Clarke S, 2018, ‘A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis’, npj Systems Biology and Applications, vol. 4, pp. 20 - 20, http://dx.doi.org/10.1038/s41540-018-0056-1

Dr Fatemeh Vafaee

SENIOR LECTURER
Room 2106, Level 2 West, Bioscience South Building E26
T 9385 3281
E f.vafaee@unsw.edu.au,
vafaeeLab.com
babs.unsw.edu.au/fatemeh-vafaee

❖ Chaudhuri R; Krycer JR; Fazakerley DJ; Fisher-Wellman KH; Su Z; Hoehn KL; Yang JYH; Kuncic Z; Vafaee F; James DE, 2018, 'The transcriptional response to oxidative stress is part of, but not sufficient for, insulin resistance in adipocytes', Scientific Reports, vol. 8, http://dx.doi.org/10.1038/s41598-018-20104-x

❖ Ebrahimkhani S; Vafaee F; Young PE; Hur SSJ; Hawke S; Devenney E; Beadnall H; Barnett MH; Suter CM; Buckland ME, 2017, 'Exosomal microRNA signatures in multiple sclerosis reflect disease status', Scientific Reports, vol. 7, http://dx.doi.org/10.1038/s41598-017-14301-3
RESEARCH FOCUS
Genetics of neurodevelopmental disorders, human brain transcriptome dynamics in normal and disease states
Suitable for students who have majored in Molecular Biology, Biotechnology or Bioinformatics

The research in the Voineagu lab employs a combination of molecular biology, cell biology and bioinformatics. Honours projects are particularly suited for motivated students interested in neurogenetics and genomics. Honours students are involved in all aspects of our ongoing research and are encouraged to publish their work.

PROJECT 1
THE ROLE OF THE NEURONAL SPlicing FACTOR A2BP1/RBFOX1 IN AUTISM SPECTRUM DISORDERS (ASD)

ASD are among the most heritable neuropsychiatric conditions, and at the same time genetically very heterogeneous, with hundreds of genetic loci implicated in the disease (Voineagu 2012). Given the genetic heterogeneity of ASD, a challenging yet fundamental question is whether the wide variety of genetic changes ultimately dysregulate a common set of molecular pathways, amenable as therapeutic targets. We recently demonstrated that despite genetic heterogeneity, shared abnormalities of gene expression could be detected in post-mortem brain tissue from ASD cases (Voineagu et al. 2011). A key finding of this study was that the neuronal splicing factor A2BP1 (Ataxin-2 binding protein 1) was downregulated in a large subset of ASD brains. While A2BP1 has been previously implicated in ASD, the mechanisms of its transcriptional dysregulation and the functional consequences of altered A2BP1-dependent splicing in ASD remain unknown. This project aims to (a) identify the genetic and epigenetic causes of A2BP1 transcriptional dysregulation in ASD brain, (b) elucidate A2BP1-dependent alternative splicing targets in the human brain, and (c) investigate the cellular and transcriptional consequences of A2BP1 dysfunction.

PROJECT 2
GENOMIC DIVERSITY IN THE HUMAN BRAIN: THE FUNCTIONAL ROLE OF EXPANDABLE DNA REPEATS

Although genetic variation can potentially occur anywhere in the genome, certain genomic regions are particularly susceptible to genetic changes. These regions are called hotspots of genomic instability, and are frequently underlied by repeated DNA sequences. One class of hotspots of genomic instability particularly relevant to brain function consists of expandable DNA repeats. These are tandem DNA repeats, most often trinucleotide repeats (TNRs) such as (CGG)n, (CAG)n, (GAA)n, which have an intrinsic propensity to increase in length during germline transmission. TNR expansions cause more than 30 neuro-psychiatric disorders, including Huntington’s disease, Fragile X syndrome and Friedreich’s ataxia (Mirkin 2007A). A surprising characteristic of human disorders caused by TNRs is that they affect primarily the brain (Mirkin 2007), although the mutation is present in all tissues, suggesting that the human brain is particularly vulnerable to this type of genetic variation. Somatic TNR expansions have been documented in the human brain at some of the TNR disease loci (Telenius et al. 1994; McMurray 2010). However, the human genome contains over 30,000 TNRs (Kozlowski et al. 2010) and whether somatic TNR expansions occur in the brain on a genome-wide scale is currently unknown. This project aims to identify somatic TNR instability events in the normal human brain and assess their effect on gene expression.

Recent publications by our Honours* students:


More detailed information on projects and ongoing research is available on the lab website: voineagulab.unsw.edu.au
We work on unusual model species that are uniquely placed in the vertebrate phylogeny to unravel mysteries surrounding the evolution of sex chromosomes and their epigenetic regulation.

**PROJECT 1**
**DNA METHYLATION AND X CHROMOSOME INACTIVATION**

Dosage compensation is required to balance gene expression from the X chromosome between males (which only have one X) and females (with two Xs). X chromosome inactivation (XCI) is one aspect of dosage compensation, and is arguably the most spectacular example of epigenetic silencing in mammalian genomes. After decades of work in the field, we have recently demonstrated that DNA methylation is important to marsupial XCI.

This project will focus on the developmental timing of when unique patterns of DNA methylation (using whole genome bisulfite sequencing) are established on the inactive X chromosome. This project will be a world first in the field of mammalian X chromosome inactivation.

**PROJECT 2**
**THE RNA BIOLOGY OF SILENCING WHOLE CHROMOSOMES**

In the somatic cells of female placental mammals, a characteristic signature of epigenetic modifications accumulates on, and transcriptionally silences, one of the two X chromosomes (a process called X chromosome inactivation). It is known that long non-coding RNAs (lncRNAs) are central for directing the epigenetic machinery, which deposits these epigenetic modifications, to target. This project will examine the lncRNAs that mediate epigenetic regulation of the X chromosome in model species, resulting in a critical understanding of how silencing of the X evolved. Techniques you will use for this project include: knockdown of critical proteins, RNA-FISH and immunofluorescence.
Almost all proteins interact with other proteins to deliver their function. These form intricate networks, including protein-protein interaction networks and signalling systems, which are critical for the regulation of the cell.

Currently, we are focused on two particular projects. The first project aims to discover the regulatory network of histones. This has a strong biological focus and is seeking to address a remarkable gap in our understanding of histone-mediated effects on gene expression. This project is a wet lab project. The second project aims to address a ‘grand challenge’ – to measure all interactions between proteins in a cell, in a single experiment. This has a more technical focus and we have wet lab and dry lab (bioinformatics) researchers working on this project. We welcome all enthusiastic students to join the team!

PROJECT 1
WHO’S CONTROLLING THE CONTROLLERS?
DISCOVERING THE REGULATORY NETWORK OF HISTONES

Histones have many post-translational modifications, notably methylation, acetylation, phosphorylation and ubiquitin. These are used in exquisite combinations, and are used by the cell to define the genes to be transcribed and to control the compaction or relaxation of chromatin. The types of modifications that occur on histones are well known and, at least for the model organism we work with, the enzymes responsible for the modifications are also known. However the regulation of these enzymes is extremely poorly understood. We want to know who is controlling the (histone) controllers. This is a fundamental question which is of relevance for every eukaryote (microbes, animals and plants). It is also of high relevance for human diseases, most notably cancers, where the modifications on histones are dysregulated.

PROJECT 2
MASSIVELY PARALLEL MEASUREMENT OF PROTEIN INTERACTIONS IN THE CELL

One of the great ‘grand challenges’ of molecular cell biology is to understand which proteins in the cell physically interact with each other, to form protein complexes, molecular machines and interaction networks. To date, interactions have been studied by either purifying protein complexes one by one, or by using two-hybrid approaches to test whether two proteins interact. We are pioneering approaches to measure hundreds to thousands of protein interactions simultaneously, in a massively parallel way. This is done on a single sample, in a single experiment. This involves the use of protein crosslinking, advanced mass spectrometry techniques, and appropriate data analysis. We have already measured > 300 protein-protein interactions in the eukaryotic nucleus in a single experiment and will be applying these approaches to other eukaryotic organelles and cell fractions. This is an exciting project using breakthrough technology.
Microbiology and Microbiomes

Cluster Strengths:

- Microbes in Health and Disease
- Microbes in the Environment

Microbes are invisible companions that intertwine our biology and support our biological and geological systems. They are big players in infectious diseases but are also fundamental to producing nutrients for plants to grow and the dynamic transformation of matter. We aim to unravel the mechanisms behind these ubiquitous microbes and their vital function in every life process. Our research in Microbiology & Microbiomes explores the importance of microbes in the environment and microbial contributions to health and disease.

Our students are encouraged to use their critical and analytical aptitude and exercise a range of genomic tools to address global topics such as archaea, climate change and food production. We endeavour to translate our research into effective methods for the control and treatment of conditions like autism, cancer and diabetes. Driven by improvements in technology and the imaginations of our researchers, we aspire to unravel the many secrets of the microbial world.
Our research is focused on unravelling the evolutionary and ecological significance of early Earth microbial ecosystems.

Stromatolites and microbial mats are model systems for studying the origins and evolution of life on our planet. They are geobiological structures composed of complex and diverse microbial communities. We have access to unique field sites on the coast of Western Australia – in particular the World Heritage site of Shark Bay - and other locations around the world. We also work closely with the Department of Parks and Wildlife to ensure these unique ecosystems are carefully monitored in the face of threats such as climate change. In particular, the impact of extreme stressors on microbial communities and critical pathways in threatened mat systems are being assessed and critical to ascertain before any irreversible ecosystem tipping points are reached.

The study of microorganisms associated with these formations may also be applied to the search of extraterrestrial life (past or extinct), particularly with the discovery of unique bio-signatures. This work thus aligns well with the goals of the Australian Centre of Astrobiology and our collaborators at NASA. Our research provides new metagenome-based models into how biogeochemical cycles and adaptive responses may be partitioned in the microbial mats of Shark Bay, including the genetic basis for novel natural product synthesis. The traditional tree of life is also in flux, and new discoveries we are making of novel organisms and pathways is affording a dynamic and holistic view of these ecosystems.

In particular we are pursuing the role of ‘microbial dark matter’ in these systems including the enigmatic group of Asgard archaea. We aim to break down the traditional distinctions between prokaryotic and eukaryotic life using the Asgardians as a ‘missing link’.

This research combines biogeochemical field measurements, laboratory analytical methods, and recent advances in functional genomics. In particular, there is the opportunity to employ next-generation sequencing platforms, including various ‘meta’ approaches (genomics, transcriptomics, proteomics). Students will use these and other modern microbial and molecular biology techniques to examine specific aspects of community function in these ‘living rocks’, from deciphering microbial interactive networks, novel adaptive responses and natural product synthesis.

Specific projects include:

- Exploring the unknown: illuminating microbial dark matter in mats
- Promiscuity in microbial mat communities: gene transfer and impact of viruses
- Hunting the elusive Asgard archaea: culture and evolutionary analyses
- The canary in the coalmine: effects of environmental change on microbial mat communities
- Living at the edge: understanding microbial survival in an extreme environment
- Look who’s talking too: communication in the third domain of life
- Mining for novel natural products: microbial mats as a source for unique metabolites

I also encourage students who want to think outside the box, so I always welcome ideas for other projects and happy to workshop potential!
RESEARCH FOCUS
Exploring soil microbial processes in Antarctic and sub-Antarctic environments
Suitable for students who have majored in Microbiology or Biotechnology and excelled in Environmental Microbiology (MICR3071) or Microbial Genetics (BABS3021).

Associate Professor Belinda Ferrari
(ARC FUTURE FELLOW)
Room 4104, Level 4 West Bioscience South Building E26
T 9385 2032
E b.ferrari@unsw.edu.au
babs.unsw.edu.au/belinda-ferrari

RESEARCH PROJECTS MICROBIOLOGY AND MICROBIOECOSYSTEMS

PROJECT 1
ATMOSPHERIC CARBON FIXATION; A NOVEL BIOCHEMICAL PROCESS DOMINATING POLAR DESERT SOILS

The Ferrari lab recently discovered a biodiversity hotspot in the Windmill Islands, eastern Antarctica, where bacteria belonging to two novel phyla – WPS-2 and AD3 – dominated the site. We used shotgun sequencing to recover genomes from soils from this site and found that the majority of the community present are potentially fixing carbon through the consumption of molecular hydrogen and carbon monoxide gas.

The aim of Project 1 is to validate atmospheric carbon fixation as a novel primary production strategy in nutrient-starved polar desert soils. Methods to be applied include novel culturing, DNA-SIP/FISH, next generation sequencing, gas chromatography, and data mining to isolate the first trace gas fixer from this environment for characterisation.

PROJECT 2
BIOREMEDIATION OF ANTARCTIC SOILS

This project will combine molecular and chemical techniques to evaluate the success of bioremediation efforts currently underway at Casey station, in eastern Antarctica. The project will use quantitative PCR, barcode tag sequencing and multivariate analyses. The Ferrari lab and this project involve a ongoing collaboration with the Risk and Remediation group at the Australian Antarctic Division. Thus, the project has real industry outcomes that will provide immediate benefit to the sensitive Antarctic environment.

Figure 1. Mitchell Peninsula, Antarctica: a nutrient-limited desert that hosts a unique microbial community that uses trace gases to survive.

Figure 2. Casey station where bioremediation of fuel spills is ongoing using engineered biopiles combined with nutrient amendment.
Infectious diseases caused by pathogenic bacteria are a major threat to human health. Our group takes a multi-disciplinary approach to study pathogenic bacteria. We use omics (genomics, transcriptomics and proteomics) approaches to address how pathogens arise and cause disease, how they evolve and adapt – and how to identify these pathogens. Currently our research group includes 2 postdoctoral associates, 1 Bioinformatician, and 6 PhD students.

Projects on respiratory tract pathogen *Bordetella pertussis*

Pertussis, commonly known as whooping cough, is an acute respiratory disease caused by *B. pertussis*. Despite widespread vaccination, pertussis remains a public health burden. Australia is currently experiencing a prolonged pertussis epidemic, with nearly 40,000 cases at its peak in 2011.

**PROJECT 1**

**PROTEOMIC ANALYSIS OF *B. PERTUSSIS* DURING IN VIVO ATTACHMENT TO HUMAN RESPIRATORY EPITHELIAL CELLS**

The current resurgence of pertussis has spurred renewed interest in understanding the pathogenesis of *B. pertussis* infections. Currently, most proteomic studies have been performed under in vitro conditions which may not reflect the proteomic changes of the bacterium during infection. The aim of this project is to elucidate key proteomic changes which contribute to colonisation when *B. pertussis* cells are co-cultured with human respiratory epithelial cells. This project involves proteomics, mass spectrometry, tissue culture and bioinformatics analysis.

**PROJECT 2**

**ELUCIDATING ESSENTIAL GENES IN *B. PERTUSSIS* UNDER INFECTION RELEVANT CONDITIONS**

To combat the global re-emergence of pertussis, an improved pertussis vaccine is required to better target current strains. The simplest strategy to improve the vaccine is the addition of new antigens. Essentials genes required for infection would be ideal targets to prevent adaptation as these genes cannot be inactivated. This project will use TraDIS to elucidate the essential genes in *B. pertussis* under different infection relevant conditions. TraDIS is a technique that combines transposon mutagenesis and genome sequencing to determine the essentiality and function of every gene under specific conditions.

**Projects on the use of new genomic methods to study major bacterial pathogens (co-supervised by Dr Michael Payne)**

In the past decade Next generation sequencing (NGS) has provided unprecedented amounts of genomic data for many bacterial pathogens. NGS has been increasingly employed to prospectively identify and track outbreaks as well as to define and examine large scale population structures and trends. NGS has major advantages over other pathogen typing methods as it promises a standardised universal solution for high-resolution typing. We have developed new bacterial typing methods that utilise whole genome sequencing data to cluster bacterial strains into groups of related isolates.

**PROJECT 3**

**GENOMIC TYPING AND GLOBAL EPIDEMIOLOGY OF NEISSERIA GONORRHOEAE**

*Neisseria gonorrhoeae* causes the sexually transmitted infection, gonorrhoea and infected an estimated 87 million people in 2018. The number of isolates with whole genome sequencing data available has grown to over 13,000 and is increasing rapidly. This project will use these data to develop a standardised new genomic typing system with an aim to provide insights into the spread of antimicrobial resistance and global spread of *Neisseria gonorrhoeae* infections.

**PROJECT 4**

**GENOMIC TYPING AND GLOBAL EPIDEMIOLOGY OF SHIGA TOXIN PRODUCING E.COLI**

Shiga toxin producing *E. coli* (STEC) is an important foodborne pathogen responsible for more than 265,000 illnesses in the United States and 2.8 million infections globally annually. STEC is a diverse collection of *E. coli* that can produce Shiga toxins and causes a range of diseases including diarrhoea, bloody diarrhoea, haemorrhagic colitis and haemolytic uremic syndrome. Infections are often due to the contamination of food ranging from sporadic cases to large scale outbreaks. There are over 40,000 STEC genomes available. This project will use these data to develop a standardised new genomic typing system to detect outbreaks and to provide insights into the evolution and global epidemiology of STEC.

Recent publications:

Opportunistic invasive fungal pathogens cause over two million life-threatening infections per year world-wide with mortality rates ranging up to 95 percent. The number of deaths per year is greater than those attributed to malaria, breast cancer or prostate cancer. Bloodstream infections caused by *Candida* species (candidaemia) are the most frequent life-threatening invasive fungal infections, with the majority caused by one species, *Candida albicans*.

*C. albicans* colonises the gut of most healthy individuals but does not usually cause serious disease because the physical barriers between our gut and the bloodstream, combined with our immune defences and the suppressive powers of the indigenous gut microbiota, prevent these infections. However, this opportunistic pathogen can cause serious, life-threatening disseminated disease when these barriers and defences are compromised (e.g. seriously ill patients in the ICU, during cancer chemotherapy or immunotherapy, organ/stem cell transplantation, or when the gut microbiota is disturbed), which renders them vulnerable to infections from the *C. albicans* that colonises their gut. Despite the availability of antifungal drugs, over 40% of these systemic infections are fatal in certain patient groups.

There is therefore an urgent clinical need for the development of new therapies for invasive candidiasis which research in my group aims to address in innovative ways.

**PROJECT 1**
**DEVELOPING MICROBIAL THERAPEUTICS TO CLEAR *CANDIDA ALBICANS* COLONISING THE COLON**

Utilising a novel *in vitro* system which mimics conditions in the human colon, projects in this area are aimed at advancing our understanding of the mechanisms by which this major pathogen adapts to and evolves in a key host niche, how this adaptation can be compromised by natural bacterial components of certain healthy GI microbiota, and how, in the future, this can be exploited to prevent *C. albicans* infections arising from the GI tract.
Our research focuses on the role of microorganisms and immunogenetics in the aetiology of gastrointestinal disease. We seek to understand the role of the gastric pathogen *Helicobacter pylori* on the intestinal microbiota and the effect of host genetic polymorphisms in Crohn’s Disease (CD) and ulcerative colitis (UC), both forms of Inflammatory Bowel Disease (IBD). A further area of our research studies is to understand the role of *H. pylori*-induced inflammation in gastric cancer (GC) by addressing issues that are crucial to the host immune response to this bacterium. This could lead to the identification of novel markers of disease susceptibility, potentially resulting in intervention strategies and/or treatments for GC, the third leading cause of cancer-related deaths worldwide. In addition, it has been suggested that dysbiosis in the stomach is dynamic and correlates with progression to GC. Given that *H. pylori* gradually disappears from the gastric mucosa upon the development of intestinal metaplasia, identification of another microbial signature associated with disease progression could improve prevention of GC. Thus, we are currently investigating the role of gastric dysbiosis in gastric carcinogenesis. All projects involve a range of cutting-edge technologies, including high-throughput sequencing, genome editing, gastrointestinal organoids, bacterial community analyses, electron microscopy and confocal microscopy as well as more basic techniques such as cell culture, bacterial cultures, real-time PCR, ELISA, Western blotting, 2D gel electrophoresis and mass spectrometry.

**PROJECT 1**
**THE INFLUENCE OF *H. PYLORI* INFECTION ON THE GASTROINTESTINAL MICROBIOTA OF IBD PATIENTS**

IBD is a chronic relapsing idiopathic inflammatory disease of the gastrointestinal tract, whose cause remains unclear. The overall aim of this Honours project is to use highly sensitive cutting-edge technology to identify specific bacteria or groups of bacteria that may be associated with IBD. In addition, we aim to elucidate the protective effect of *H. pylori* on IBD development by investigating the effect of *H. pylori* infection on the intestinal flora and the immune response.

**PROJECT 2**
**THE ROLE OF AUTOPHAGY IN *H. PYLORI*-RELATED GASTRIC CANCER**

*H. pylori* has been causally linked to the development of gastritis, peptic ulcer disease (PUD) and GC. Although 50% of the world’s population is infected with *H. pylori*, only a small percentage develops PUD (10-15%), B cell MALT lymphoma (<1%) and GC (1-3%). These findings suggest that factors other than *H. pylori* infection (environmental risk and host genetic susceptibility) may contribute to more serious disease outcomes. We are interested in the role of host genetic polymorphisms in genes involved in innate immunity including autophagy, NOD-like receptors and Toll-like receptors.

**PROJECT 3**
**DO MICROBIAL METABOLITES CONTRIBUTE TO GASTRIC CARCINOGENESIS?**

Dysregulated metabolism is currently known as a critical factor for cancer development, maintenance, and metastasis while tumour metabolic activity has been correlated with recurrence and poor prognosis. This project will advance our understanding of the underlying mechanisms by which metabolites might contribute to gastric carcinogenesis, and how key organisms in the stomach modulate these processes.

**Recent publications:**

We are interested in understanding how bacteria and viruses evolve. We analyse genetic data and develop mathematical models to explain and predict the population dynamics of pathogens and other microorganisms. These projects would suit students interested in microbial evolution who would like to develop their skills in bioinformatics, computing and/or data analysis. Alternatively, you might be a student with a background in quantitative sciences such as maths, statistics, computing, physics or engineering and a growing interest in biology. These projects can be tailored to fit the academic background, research interests and career goals of individual students.

PROJECT 1
END OF AN EPIDEMIC

At the time of writing this blurb in mid-2020 the coronavirus pandemic has so far killed half a million people in a few months and continues to rage around the world. In some countries like New Zealand SARS-CoV-2 has been brought under control with strict lockdown measures. Predicting what will happen next is hard given the multiple uncertainties - the timing of an effective safe vaccine or drug treatment, the possibility of new waves of uncontrolled infection. In Australia the epidemic has been suppressed to a low number of new cases detected daily. Some cases are residents returning from overseas and some are due to local transmission. When and how will the epidemic in Australia end? The dynamics of this coronavirus have been intensively studied around the world in recent months. You will use knowledge gained through these efforts to construct and analyse mathematical models of alternative scenarios of the end of the epidemic in Australia. This project will require skills in mathematical modelling, including probability theory, and skills in computer programming.

PROJECT 2
DRUG-RESISTANT TUBERCULOSIS

Tuberculosis kills 1.5 million people each year and although effective treatment exists the prevalence of drug resistance is rising. Some strains of the TB bacterium are resistant to all first-line drugs. This project aims to understand patterns of drug resistance in tuberculosis infections by analysing molecular epidemiological data using available and new software. This work will be complemented with computer simulations of TB epidemiology and evolution.

PROJECT 3
PATHOGENS EVOLVING BETWEEN AND WITHIN HOSTS

Pathogens are under strong selection to transmit effectively between hosts. They are simultaneously under selection to reproduce efficiently within hosts. How do these two processes interact? This project considers the evolution of pathogens as a process of natural selection operating at multiple scales. Using a computer simulation model of between and within host dynamics you will predict properties of sequenced isolates as a product of the joint dynamics.

For more information about us see tanakalab.unsw.edu.au

Figure: The grey shape shows the course of an epidemic without any control measures using a standard SEIR model. The blue shape shows the effect of relatively weak control which reduces transmission for a period of time between the two blue vertical lines. This strategy lowers case numbers but creates a second wave. The dark flat shape shows the effect of strong control measures, resulting in a slow decay in the number of infections.
My lab seeks to understand how genes involved in pathogenicity and antibiotic resistance are regulated in bacterial pathogens. A major focus of the lab is understanding how pathogens use regulatory non-coding RNA (ncRNA) to control virulence. We are using cutting edge RNA-sequencing techniques and molecular biology to study these processes and reveal exciting new gene regulatory pathways that contribute to disease.

PROJECT 1
UNDERSTANDING HOW NON-CODING RNAs CONTROL ANTIBIOTIC RESISTANCE IN THE SUPERBUGg, MRSA.

Methicillin resistant *Staphylococcus aureus* (MRSA) is a leading cause of bacteraemia, infective endocarditis and osteomyelitis. Treatment of severe MRSA bacteraemia is limited to the last-line antibiotic vancomycin and the World Health Organisation (WHO) has designated MRSA a Priority 2 pathogen for development of new interventions. We have discovered that a non-coding RNAs (the we have named SvaR) that controls cell wall turnover is required for intermediate resistance to vancomycin. In this project, we aim to understand how SvaR is regulated and why SvaR is required for vancomycin resistance in this important human pathogen. This project will involve genetic manipulation of MRSA, mutagenesis, CRISPRi knockdowns, and GFP reporters to characterise these pathways.

Please feel free to contact me at j.tree@unsw.edu.au if you would like to discuss research projects in the lab.

PROJECT 2
HIGH-THROUGHPUT ANALYSIS OF SRNA FUNCTION USING A BARCODED DELETION LIBRARY

We have demonstrated that EHEC produces at least 55 novel regulatory non-coding RNAs that are only found in pathogenic *E. coli*, however we know very little about the function of these RNAs in EHEC pathogenesis. In this project, we aim to construct a library of barcoded sRNA deletions using recombinering and/or CRISPR/Cas9-mediated deletion. Using this library we will simultaneously assay the fitness of every non-coding RNA by high-throughput DNA sequencing to measure the abundance of each deletion. This project will involve genetic manipulation of a bacterial pathogen, recombinering, CRIPR/Cas9-mediated recombinering, and high throughput DNA sequencing.

PROJECT 3
IS CARBON METABOLISM CONTROLLING PHTHOGENESIS IN ENTEROHAEMORRHAGIC *E. coli*

In collaboration with colleagues at the University of Edinburgh, UK we have shown at carbon starvation and carbon metabolism pathways communicate through regulatory non-coding RNA. This project will seek to understand how two major regulatory RNAs interact to control carbon metabolism in the model bacterium, *E. coli*. These RNAs also control virulence gene regulation in EHEC and this project will more broadly seek to understand how major carbon metabolism regulators control virulence gene expression. This project will use genetic modification of pathogenic *E. coli*, mutagenesis, cutting edge RNA-sequencing techniques, and GFP reporters to characterise these pathways.
The Molecular Microbiology Laboratory lab is part of the School of Biotechnology and Biomolecular Sciences (BABS) and located in state-of-the-art facilities. Research in this multi-disciplined group encompasses molecular virology, antiviral drug discovery, viral evolution, viral biocontrol and paleovirology.

**PROJECT 1**
**NOROVIRUS REPLICATION AND EPIDEMIOLOGY**

Norovirus is the major cause of gastroenteritis outbreaks worldwide and is responsible for around 219,000 deaths each year. Major pandemics of norovirus gastroenteritis occur around every three years, with six pandemics since 1998. These pandemics are associated with novel noroviruses from a single genotype (GII.4), which escape herd immunity through both antigenic drift and shift. Our group is part of international and national networks that trace and track pandemic noroviruses globally. We first identified and characterised two of the six pandemic viruses; Hunter 2004 and Sydney 2012, both responsible for global pandemics of gastroenteritis. We have developed a number of norovirus molecular detection and bioinformatic tools over the last few years for molecular virology studies. The aim of this project is to conduct a detailed molecular epidemiological and evolutionary analysis of Australian noroviruses, using both clinical samples and wastewater. The project will determine if current outbreaks are associated with the emergence of novel virus variants or recombinant (hybrid) viruses.

**PROJECT 2**
**ANTIVIRAL RESEARCH: DEVELOPMENT OF SMALL COMPOUND ANTIVIRALS**

Traditionally, antiviral drugs have been ‘one drug, one bug’, meaning a new drug is required to treat every virus. There is an active hunt for new, effective antivirals to treat and prevent viral infections, and drugs which target multiple viruses could be invaluable as a first line of defence. Our research focuses on the development of broad-spectrum, small compound antivirals, to combat positive sense RNA viruses in the Caliciviridae (norovirus, feline calicivirus), Flaviviridae (hepatitis C virus, Zika virus, dengue virus) and Hepeviridae (hepatitis E virus). Our main target is the viral RNA-dependent RNA polymerase (RdRp) because of its key role in viral replication. We have produced purified, soluble and active recombinant RdRps from many viruses, using Escherichia coli expression systems and used these to identify novel RdRp inhibitors. Promising inhibitors are taken forward to cell culture where we use live viruses and replicons to test their suitability as broad-spectrum drugs. In silico modelling is also performed on promising compounds to predict possible binding interactions. The aim of the antiviral project is to conduct screening campaigns against the viral RdRps to identify lead compounds for potential antiviral therapeutics.

**PROJECT 3**
**DISCOVERING NEW CANE TOAD VIRUSES**

In 1935, 101 Hawaiian cane toads were introduced into Queensland to control the cane beetle. Now, over 2 billion feral toads ravage 1.2 million km² of northern Australia and threaten native species. One way to eliminate the cane toad is to find new, deadly, toad-specific viruses.

Previous cane toad viruses were not suitable for biocontrol as they could affect native amphibians. The aim of this project is to increase our understanding of the cane toad and to find new viruses that can infect it. Our lab is collaborating with several institutions and we have already sequenced the entire 2 Gb cane toad genome for the first time. We are performing RNA-seq and PCR-based techniques on toad tissues sourced from diverse locations to find viruses that are infecting toads in nature. This project involves a combination of wet lab work involving nucleic acid and virus extraction from toad tissues, and PCR amplification methods to find viruses. This project also involves bioinformatic analysis of toad RNA-seq data and genomic data to find virus-like sequences.

**PROJECT 4**
**PALEOVIROLOGY: FINDING ANCIENT VIRUSES USING BIOINFORMATICS**

The study of ancient viruses is termed paleovirology. The aim of this project is to find ancient viruses, or ‘fossil remnants of viruses’. The genomes of animals and insects contain traces of past viral infections through the integration of viral genetic material into the host genome, termed endogenous viral elements (EVEs). These viral fossils can be used to find viruses that existed thousands of years ago. Around 5% of the human genome is comprised of EVEs, of which the vast majority are retroviruses that naturally insert their genomes into the host genome as part of their life cycle. For other viruses, germ line integration is rare, but has been documented in many organisms. Using bioinformatics, our lab aims to find EVEs in diverse groups of animals. Using genomes from mosquitoes, flies, and ticks, we have identified hundreds of EVEs, and identified unique patterns and a link to innate immune pathways in the blacklegged tick Ixodes scapularis. We aim to find more viral fossils in the genomes of other animals, including marsupials, which are ecologically threatened.
Multiple projects are available. These projects provide research training in bacterial pathogenesis, host response to infection, mucosal immunology, bacterial genome and metagenomic analysis, molecular diagnosis of bacterial infection, precision antibiotics, vaccines for mucosal associated bacteria, or cancer immunotherapy-associated gut microbes.

**PROJECTS ON CAMPYLOBACTER CONCISUS AND INFLAMMATORY BOWEL DISEASE (IBD)**

*C. concisus* is a commensal oral bacterium but some strains may cause enteric diseases. We found that *csep1-6bpi* positive *C. concisus* strains may cause Crohn’s disease (a major form of IBD). The *csep1-6bpi* gene, which encodes a superantigen homologue, is located in the pICON plasmid or the *C. concisus* chromosome. Two Honours projects are available. One project focuses on the *C. concisus* bacterium, students can choose to work on one of the following research areas including charactering bacterial virulence factors, analysing *C. concisus* genomes, examining the relationship between *C. concisus* and other gut microbes, or validating molecular diagnostic methods for detection of virulent *C. concisus* strain in clinical samples. The second project focuses on host response to *Csep1* and *C. concisus*.

**PROJECTS ON PRECISION ANTIBIOTICS AND VACCINES**

Two projects are available. The first project aims to develop precision antibiotics to specifically kill/inhibit individual bacterial species. As some bacterial species in the oral and gut microbiota may cause IBD. The development of precision antibiotics will enable selective elimination/inhibition of harmful bacterial species without affecting the balance of microbiota in the gastrointestinal tract. Precision antibiotics may also be used to treat antibiotic resistant pathogenic bacterial species. The second project is to identify bacterial components that can be used as vaccines to control *C. concisus* and other mucosa-associated bacterial pathogens.

**PROJECTS ON CANCER IMMUNOTHERAPY-ASSOCIATED GUT MICROBES**

Blockade of immune checkpoint proteins is a means of cancer treatment. Recent studies found that some bacterial species in the gastrointestinal tract may affect the efficacy of immune checkpoint blockade therapy. This project investigates the mechanisms by which gut bacterial species affect immune checkpoint blockade therapy, aiming to provide additional strategies to improve cancer immunotherapy efficacy.
cells and tissues for medical and therapeutic purposes such as vaccinations. Other developments have included DNA fingerprinting in forensics and pioneering crop modifications in agriculture. Our research centres on the areas of Synthetic Biology and Metabolism and Molecular Cell Biology. We incorporate molecular genetics, stem cell biology, microscopy, computer science and epidemiology to answer unsolved biological questions and train the next generation of life scientists.

RESEARCH PROJECTS

MOLECULAR AND CELL BIOLOGY

CLUSTER STRENGTHS:

❖ Metabolism and Metabolic Disorders
❖ Structural and Synthetic Biology

Since traditional biology focuses on living organisms as a whole, Molecular and Cell Biology explores the components and interactions that make up a cell. This gives us a deeper understanding of cell function and why diseases and disorders happen on a molecular level.

Molecular and Cell Biology has been pivotal in a wide range of fields and revolutionised the ability to manipulate cells and tissues for medical and therapeutic purposes such as vaccinations. Other developments have included DNA fingerprinting in forensics and pioneering crop modifications in agriculture. Our research centres on the areas of Synthetic Biology and Metabolism and Molecular Cell Biology. We incorporate molecular genetics, stem cell biology, microscopy, computer science and epidemiology to answer unsolved biological questions and train the next generation of life scientists.
My research group currently focuses on two streams of research:

1. The directed, molecular evolution of the bacterial flagellar motor to ascertain how the motor arose and to learn what constrains the evolutionary pathways that govern the emergence of such complexity.

2. Bottom-up synthetic biology using DNA nanotechnology to control lipid interactions to investigate mechanosensing and build systems for intracellular communication.

### PROJECT 1
**EVOLUTION ACROSS INTERFACES**

In this project we explore the directed evolution of the flagellar motor in the lab by evolving it to swim under different energy sources and selecting for motility. Recent work in antibiotic resistance (eg by Michael Baym) has shown that the resistance of antibiotics occurs in lockstep when progressing through 10-fold increases in antibiotics. We aim to explore how motility evolves across interfaces, when a bacterium faces a change in environment between, for example, H+ and Na+ environments, and how the bacteria adapts to dwindling nutrient across this interface. This project has scope for designing and building custom tanks to optimise bacterial evolution using 3D printing and prototyping, as well as investigating microbiology and bacterial motility in multiple dimensions using layered swim devices.

### PROJECT 2
**ORIGINS OF MOTILITY**

The evolutionary origins of the bacterial flagellum have been a subject of scientific and public controversy – how can evolution produce such a complex system? We believe we can make progress on the issue by updating old phylogenetic work with new datasets and improved models, and combining this with experimental evolution work being done in our labs.

The project will be to assemble a well-organized database of flagellar proteins and explore sequenced bacterial genomes with genome browsers and sequence-similarity searches. The student will identify flagellar proteins and their evolutionary relatives, including recording their position in the genome. The student will also plan and conduct phylogenetic analyses, and then use synthetic biology to recreate these ancestors in a contemporary microbial ‘Jurassic Park’.

### PROJECT 3
**REGULATION OF MEMBRANE PROTEIN INSERTION IN ARTIFICIAL BILAYERS USING DNA ORIGAMI**

Our droplet hydrogel bilayer system is an artificial bilayer system for interrogating membrane proteins, but it also allows us to explore new forms of synthetic biology where we can add individual protein function to a droplet, such as touch sensitivity or light sensitivity. Using a DNA origami nanostructures we can protect and controllably release our blocking DNA structures to direct the fusion of liposomes and control which reactions take place where in these droplets. This allows us to trigger functionality, on demand, using light and electrical signals. This project involves in vitro synthetic biology, DNA and lipid nanotechnologies and microscopy.

### PROJECT 4
**MECHANISM OF MECHANOSENSING IN PIEZO1**

Droplet Hydrogel Bilayers are capable of simultaneous single channel current and fluorescence measurements. They have been used to characterise the functionality of alpha-haemolysin for use in nucleobase recognition in DNA sequencing and they have been arranged in multiple arrays to parallelise high throughput channel measurements. We use this platform to investigate other force-sensitive ion channels which are generally linked to cancer progression and post-traumatic osteoarthritis. Our next goal is to combine fluorescence with electrophysiology using labelled constructs for single molecule fluorescence.
RESEARCH PROJECTS Molecular and Cell Biology

Associate Professor Wallace Bridge
Room 420C, Level 4 West, Biological Sciences North Building D26
T 9385 1297
E w.bridge@unsw.edu.au
babs.unsw.edu.au/wallace-bridge

PROJECT AREA
ANTIOXIDANTS: γ-GLUTAMYLCYSTEINE

γ-glutamylcysteine (GGC) is the immediate precursor to the tripeptide glutathione, which is considered the "master" antioxidant for all aerobic organisms. Many human disorders and diseases such as Alzheimer’s, Parkinson’s – and ageing itself – are related to the body’s inability to maintain sufficient levels of glutathione within its cells.

It is widely thought in the scientific community that any treatment that can replenish glutathione levels in cells would offer broad therapeutic benefits. For many instances of chronic glutathione depletion, the problem lies with damaged regulatory control of the enzyme responsible for synthesising GGC (GGC synthetase) from glutamate and cysteine. That is, GGC becomes a limiting substrate for the final synthesis reaction catalysed by glutathione synthase (condenses GGC with glycine to form glutathione). We have shown in a published human clinical trial that orally administered GGC can significantly increase glutathione levels in white blood cells, suggesting that GGC has systemic bioavailability. Further human clinical trials to explore any efficacy of GGC in the treatment of various diseases are being planned.

In 2006, my research group developed a biocatalytic process for GGC manufacture which we patent protected. Our industry partner is now manufacturing and selling GGC containing dietary supplements in the US, where GGC has “GRAS” (generally regarded as safe) status.

The 2021 Honours projects will continue our exploration of the therapeutic potential of GGC using human cell line models for glutathione depletion and oxidative stress.

PROJECT AREA
PHAGE THERAPY

We are collaborating with several research groups and industry partners to explore the potential to develop bacteriophage (phage) cocktails that are effective in controlling bacterial contamination in industrial processes and in the treatment of bacterial infections in humans and animals. The 2021 Honours projects will involve the isolation and genetic characterisation of lytic phage capable of infecting and killing bacteria of interest. The use of modern molecular biology gene editing tools (e.g. Crispr-Cas9) will be investigated for their potential to modify the host specificity of phage types to target problematic strains of contaminants and pathogens.

In vivo and in vitro models for exploring potential health benefits of the glutathione precursor, gamma glutamylcysteine
2. The use of bacteriophage as biocontrol agents for therapeutic and industrial applications.

Suitable for students who have completed any BABS major
Cholesterol is a vital and versatile molecule that has become a byword for heart disease risk. In fact, the cells in our body actually need cholesterol, and too little results in devastating developmental disorders. However, too much can contribute to several diseases, including atherosclerosis and cancer. Our bodies have therefore engineered an elaborate system for keeping the cholesterol content of our cells tightly controlled. The overall goal of our research is to understand more about how our cells control cholesterol levels.

PROJECT 1
NEW FACTORS IN ACHIEVING CHOLESTEROL BALANCE

An imbalance of cholesterol plays a role in numerous diseases. Therefore, knowing precisely how cells regulate their cholesterol levels is central to understanding the development of these diseases, and to identify possible new treatments. Only one of the 20+ enzymes involved in cholesterol biosynthesis is targeted clinically (by statins). The statin class of drugs, worth >$30 billion a year, inhibit a very early step in cholesterol synthesis and have been effective in treating heart disease, but are not without their side effects. Very little attention has been paid to later steps in the pathway. This project will investigate the regulation of new control points in cholesterol synthesis, which have been largely overlooked in the past.

PROJECT 2
CHOLESTEROL AND CANCER

Cancer is a disease characterised by increased cellular replication and spread beyond the normal location in the body. A hallmark feature of cancer cells is their abnormal metabolism compared to normal cells. Notably, cells need cholesterol to grow and proliferate and mechanisms to accumulate cholesterol are far more common in cancer cells. Our lab discovered a connection between a major player involved in maintaining cholesterol balance in animal cells and a key proliferative pathway that is overactive in many cancers, including prostate cancer. This project investigates novel ways to modulate and decrease cellular cholesterol levels, which may inform the development of new anti-cancer therapies.

METHODS

Mammalian cell culture, recombinant DNA techniques (cloning and mutagenesis), fluorescence microscopy, real-time PCR, gene/siRNA transfection, luciferase reporter assays, SDS-PAGE and Western blotting.

Suggested references (available on request)


Figure 1: Cholesterol changes the shape of the cholesterol synthesis enzyme SQLE. Chua et al., JBC 2017
Cancer cells metabolise nutrients differently than non-cancerous cells. This altered metabolism enables cancer cells to rapidly divide, move in the body (metastasize), and evade the immune system. The goal of my research is to find new ways to target this feature (altered metabolism) for anti-cancer therapy. The first project available in my team centres on developing new drugs that selectively kill cancer cells by targeting their metabolic vulnerabilities. The second project focuses on understanding the role of a lesser-known glucose transporter (GLUT6) in cancer cell biology.

**PROJECT 1
DEVELOPING NEW DRUGS TO SELECTIVELY KILL CANCER CELLS**

Cancer cells reprogram their metabolism to survive and thrive in our bodies. Therefore, one way to kill cancer cells is to target their Achilles heel— that is, the way they metabolise nutrients. Our lab performed a drug screen to identify novel molecules that disrupt the metabolism of cancer cells by interfering with oxidative metabolism. From this screen we identified an exciting new molecule that kills cancer cells while leaving many ‘normal’ cells unharmed (Byrne et al. 2020). By working with medicinal chemists at UNSW, we have developed new and improved molecules based on the structure of the original molecule. However, we need to perform further testing of these molecules to see how they work in vitro (in human cell cultures) and whether they can eradicate cancer in vivo (mouse cancer models). Results from this project could lead to cancer therapies that have less side effects than current chemotherapy agents. These drugs could therefore dramatically improve the quality of life of many cancer patients.

**Reference**

**PROJECT 2
DETERMINING THE ROLE OF GLUT6 IN ENDOMETRIAL CANCER CELL BIOLOGY**

Endometrial cancer is the most common gynecological malignancy in Australia and the incidence of this cancer is rising. My research has shown that a lesser-known glucose transporter (GLUT6) is upregulated in endometrial cancer and that knocking down this protein inhibited glucose metabolism and survival of endometrial cancer cells (Byrne et al. 2014). This was the first study to indicate that GLUT6 plays an important role in cancer cells. I then developed a GLUT6 knockout mouse and showed that loss of GLUT6 does not have detrimental effects to mice, which suggests that GLUT6 may be a good target for cancer therapy because loss of this protein may not effect healthy tissues (Byrne et al. 2018). Recently our lab showed that GLUT6 expression is driven by an inflammatory signaling pathway (NF-κB) in endometrial cancer cells (Caruana & Byrne 2020). This research project will involve determining whether GLUT6 overexpression alters endometrial cancer cell growth in vitro and in vivo (in mice), their ability to move (migrate/invasive), and response to stressors such as chemotherapy agents or hypoxia (low oxygen). These experiments will help determine whether GLUT6 represents a good therapeutic target for endometrial cancer because they will help us gain a better understanding of why GLUT6 is upregulated/overexpressed in this malignancy.

**References**
The folding and assembly of proteins into intricate supramolecular architectures is critical to many biological functions, ranging from cellular scaffolding provided by cytoskeletal proteins to the encapsulation of nucleic acids in viral capsids. Improvements in our understanding of protein assembly is enabling the creation of biomaterials that mimic and complement biological systems. The research projects in my laboratory use synthetic biology to build functional materials and devices from self-assembling proteins.

**PROJECT 1**
**CONDUCTIVE PROTEIN NANOWIRES FOR BIOELECTRONICS AND BIOSENSORS**

The recent discovery of conductive protein-based nanowires produced by bacteria has potential applications in the development of bioelectronics and biosensors. Exploiting this conductivity and the ability of proteins to self-assemble into complex structures may facilitate the fabrication of structured nanoscale devices that can directly interface with biological systems (e.g. enzymes or cells). This project will create novel protein nanowires by alignment of redox-active proteins on filamentous scaffolds. Subsequently, the protein nanowires will be used to mediate the transmission of electrons for novel electrical devices, biosensors or bio-batteries.

**PROJECT 2**
**DESIGN OF SYNTHETIC TRANSCRIPTION FACTORS**

An aim of synthetic biology is to engineer useful genetic systems inside living cells – for example, to make cells produce drugs or detect changes in the environment. The challenge is: can synthetic genetic circuits interfere with the rest of the cell? In this project, we will build synthetic transcription factors (synTFs) that can be used to regulate synthetic genetic circuits. Conversely, synTFs can also be used to modulate natural genes in a controllable manner. The applications of synTFs extend from the design of synthetic living systems to targeted gene/protein therapies for genetic diseases.

**PROJECT 3**
**SELF-ASSEMBLING BIOMATERIALS FOR NANOTECHNOLOGY**

The fabrication of nanoscale devices requires architectural templates upon which to position functional molecules in complex arrangements. Protein and DNA are attractive templates for nanofabrication due to their inherent self-assembly and molecular recognition capabilities. This project will engineer a new class of biotemplates that use DNA origami to link filamentous proteins into three-dimensional templates of controllable size and symmetry. Subsequently, these novel biotemplates will serve as a foundation upon which to build functional nanodevices including molecular machines and biosensors.

Suggested references (available on request):

RESEARCH FOCUS

Mechanisms linking altered nutrient metabolism to obesity, cancer and diabetes

Suitable for students who have majored in Molecular Biology, Biotechnology or Bioinformatics

RESEARCH PROJECTS

MOLECULAR AND CELL BIOLOGY

Associate Professor
Kyle Hoehn
Room 420A, Level 4 West
Bioscience South Building D26
T 9385 9399
E k.hoehn@unsw.edu.au
babs.unsw.edu.au/kyle-hoehn

Obesity: The other pandemic

According to the World Health Organization more than 1.9 billion adults worldwide are overweight and of these over 600 million are obese. Australia is more overweight than the world average, with the Australian Bureau of Statistics estimating that 67% of the adult population is overweight, including 31% obese. Current lifestyle and drug interventions are not sufficient to reverse obesity.

Obesity is associated with shortened lifespan and is a major risk factor for metabolic diseases including cardiovascular diseases, fatty liver disease, and many types of cancer. Identification of drugs that safely reverse obesity could increase healthspan, decrease disease burden, and improve quality of life on a global scale.

My lab is focused on developing new drugs that reverse obesity. Our molecules are mitochondrial uncouplers that lower metabolic efficiency so that more fat is burned to produce a given amount of ATP energy. We are seeking honours students to join projects that will test new mitochondrial uncouplers for bioactivity in vitro and for safety and efficacy to reverse obesity, reverse fatty liver disease, and slow ageing in mice.

Publications in 2020


PROJECT 1
SEARCHING FOR NOVEL ENZYMES FOR DIPEPTIDE SYNTHESIS

Gamma-glutamyl transferase is a ubiquitous enzyme and is found to have use in the production of the dipeptide gamma glutamyl cysteine. Currently, the enzyme is sourced from native mammalian tissue. This project will explore alternative native and recombinant methods to generate active enzymes for improved industrial application of this enzyme.

PROJECT 2
RECOMBINANT REDUCTIVE DEHALOGENASES (RDAses)

Reductive dehalogenases are enzymes involved in the reductive dechlorination of polychlorinated hydrocarbons, such as hexachlorobenzene. Microbial processes to degrade hexachlorobenzene and other chlorinated hydrocarbons have been described, however the anaerobic processes in particular are relatively slow, because of low cell densities, slow growth rates and low substrate concentrations. This project will aim to evaluate an alternate host for facilitating a dehalogenation process.

PROJECT 3
RECOMBINANT SPIDER SILKS

Spider major ampullate silk is nature’s toughest fibre. In order to commercialise silks for specialist functions, a recombinant approach has been pursued in bacterial and yeast hosts. The fibres generated from the proteins nonetheless have not performed as well as spider silks on tensile and other mechanical performance tests. New genomic data is now telling us that the best performing spider silks are a unique mix of MaSp1 and MaSp2 and other ampullate proteins (spidroins; e.g. MaSp3 and 4). Some of these ‘other’ spidroins have only recently been discovered and sequenced. This project will systematically isolate, amplify, and express each of the spidroins in a microbial host. The proteins will then be purified and concentrated before being spun into threads using microfluidic techniques. This work will provide us insights into the mechanisms by which the expression of particular genetic patterns and the subsequent proteins are utilized to produce, both naturally and synthetically, nature’s toughest fibres.

PROJECT 4
PATHWAY ENGINEERING FOR TERPENE BIOSYNTHESIS – INDUSTRY LINKED PROJECT

Cultured Terpenes and terpenoids comprise a large group of structurally diverse metabolites, produced predominantly by plants, with applications ranging from pharmaceuticals, agrochemicals, through to flavours and fragrances. Most eubacteria, plants and cyanobacteria share the same metabolic pathway (MEP pathway) supplying the cell with terpenes and terpenoids that fulfill various essential functions in photosynthesis, cellular metabolism, cellular defense, etc.. Besides transcriptional control of pathway gene expression, optimisation of the MEP pathway involves identifying limitations at the protein level. Soluble and functional expression of recombinant enzymes in the MEP pathway are crucial to the creation of core chassis strains.

In collaboration with researchers at Bondi, this project involves characterisation and optimisation of terpene/terpenoid synthase expression using a range of biochemical characterisation methods. Comparing expression levels of enzymes from different genetic backgrounds, enzyme fusions and solubility-tagged enzymes allows for an understanding in future rational enzyme engineering approaches and pathway optimisation. The project combines techniques in protein biochemistry (SDS-PAGE, Western Blot, chromatography techniques) and can be further extended to develop novel techniques to increase solubility and function of crucial enzymes involved in terpene synthesis.
We study mammalian metabolism and gene regulation, with the aim of identifying biological pathways to target for anti-obesity therapies. White adipose tissue can be converted to ‘beige’ adipose tissue, which burns energy to produce heat rather than storing energy. We aim to better understand beige adipose tissue so that this knowledge can be harnessed to reverse obesity.

Currently, our collaborative research group includes 2 Postdoctoral Associates, 6 PhD students and 2 Honours students. Two Honours positions will be available for 2021.

PROJECT 1
CONTROLLING OBESITY: TRANSCRIPTIONAL REGULATION OF THERMOGENESIS

Obesity is one of the Western world’s greatest medical challenges. In this project, we will investigate signalling molecules and downstream targets controlling fat cell development and energy expenditure. We are particularly interested in understanding how cells of the immune system, which naturally reside within adipose tissue, are able to signal to adipocytes and cause them to burn fat rather than store it. Our hypothesis is that eosinophils, an immune cell that resides within adipose tissue, produces signalling molecules which we call “eosinokines” that drive beiging of white adipose tissue (see schematic diagram below).

Techniques
Our projects offer the opportunity to learn a wide variety of molecular biology and cell biology techniques, including Chromatin immunoprecipitation (ChIP), Western blotting, gel shifts, subcloning and bacterial transformation, site directed mutagenesis, CRISPR/Cas9 genome editing, PCR and real-time PCR, microarrays and next-generation technologies (RNA-seq and ChIP-seq), tissue culture, transient and stable transfections of mammalian cells, reporter gene assays and flow cytometry.

Recent publications
In the brain, information is transmitted, processed and memorised by neurons. To perform these functions, neurons must grow and form networks, in which individual neurons are connected to other neurons by specialised contacts called synapses. Neurons use synapses to communicate with other neurons and to process and store information. Formation of the networks and synapses is regulated by neural cell adhesion molecules (see our review Sytnyk et al. 2017). Our laboratory uses cutting-edge techniques of modern biochemistry, molecular biology, microscopy, biophysics and bioinformatics to understand the molecular and cellular mechanisms of neuronal network formation and regulation in health and disease. We also develop new technologies aimed at improving brain performance, enhancing learning and maintaining memory by analysing properties, functions and regulation of the neural cell adhesion molecules.

**PROJECT 1**

**MECHANISMS OF THE NEURONAL NETWORK DEVELOPMENT**

Neurons must grow long axons and develop extensively branched dendrites to make synapses with other neurons. Neural cell adhesion molecules (labelled in green in the image on the left) accumulate at the growing tips of axons and dendrites and regulate the speed and direction of the growth (see our work Sheng et al., 2015). The project will investigate how growth and recognition between neurons are regulated by the key neural cell adhesion molecules. The results of this work will help to characterise molecular mechanisms linking changes in levels of neural cell adhesion molecules to abnormal brain development.

**Project 2**

**SYNAPTIC MECHANISMS OF MEMORY FORMATION AND MAINTENANCE**

The numbers and function of synapses (yellow dots in the image on the left) are regulated by neural adhesion molecules to encode memories during learning. In Alzheimer’s disease, synapse disassembly results in memory loss. It is caused by the degradation of adhesion molecules in synapses (see our work Leshchyns’ka et al., 2015). The project will study the molecular mechanisms of synapse regulation by neural cell adhesion molecules and mechanisms of adhesion loss in neurodegenerative disorders. Cellular and animal models of learning and brain disorders associated with synapse loss will be used.

**PROJECT 3**

**ENDOGENOUS AND ARTIFICIAL MODULATORS OF CELL ADHESION**

Cell adhesion molecules are cell surface glycoproteins, the function of which is regulated by neurons at different stages of brain development and in response to a variety of external stimuli, for example during learning. This project will aim to identify and characterise new endogenous regulators of cell adhesion molecules and test artificial regulators of cell adhesion molecules to analyse their pharmacological potential in various disease models. Recombinant protein production, mass spectrometry, protein-protein interaction assays, various protein analysis tools, and cellular models will be used.

**References**


❖ Sheng L et al., 2015, ‘Neural cell adhesion molecule 2 promotes the formation of filopodia and neurite branching by inducing submembrane increases in Ca2+ levels’, Journal of Neuroscience, 35:1739-52.

PROJECT
POTENTIAL USE OF CAMPYLOBACTER PHAGE TO COMBAT FOOD POISONING IN POULTRY

For Campylobacteriosis is one of the most common gastrointestinal diseases worldwide, and is caused predominantly by just two Campylobacter species, C. jejuni and C. coli, typically from poultry products. Successful clearance of Campylobacter using phages has been reported around the globe. However, there are no successful reports of phage control of Campylobacter in Australia. The aim of this study is to investigate phages that could potentially be used to decontaminate poultry products in Australia.

We are working with an industry partner to isolate new indigenous Australian Campylobacter that are relevant to the poultry industry as well as Campylobacter phages that are able to infect and lyse these Campylobacter strains.

In collaboration with a Japanese research group from the University of Kyoto, we have identified a number of Japanese phages which are able to infect and lyse Australian C. jejuni cells. We are now using whole-genome sequencing (WGS) of Australian Campylobacter strains to identify:

- the basis for Campylobacter permissiveness to phage infection.
- the evolutionary relationship between permissive and non-permissive strains

Importantly, our work has revealed that the permissive strains are generally not separated evolutionarily from the non-permissive strains and further, Australian Campylobacter are not unique from the rest of the world in terms of host receptor gene and whole-genome sequences. This finding indicates a potential for the use of phages from other countries in the Australian poultry industry.

RESEARCH FOCUS

The mechanisms by which viruses affect their host cell. Suitable for students who have majored in Molecular Biology, Biotechnology, Genetics or Medical Microbiology & Immunology

We have previously demonstrated the presence of a number of viruses (HPV< MMTV and EBV) in Australian breast and prostate cancer specimens, suggestive of a causal role. The focus is now on the use of phage as a biocontrol of food poisoning, specifically the control of Campylobacteriosis.
We work on two areas: the cellular dynamics of lipid droplets, adipocyte development, obesity and diabetes; and cholesterol trafficking in eukaryotic cells and its role in heart disease and cancer.

**PROJECT 1**
OXYSTEROl BINDING PROTEINS, INTRACELLULAR CHOLESTEROL TRAFFICKING AND NEUROLOGICAL DISEASES

Aberrant distribution of cholesterol causes heart disease and cancer. We have identified novel proteins that regulate cholesterol transport in cells. We now aim to identify additional regulators of cellular cholesterol distribution, and to understand how these proteins may regulate heart and brain function. The students will learn key techniques in cell biology such as cell culture, fluorescence microscopy etc.

Selected References


**PROJECT 2**
SEIPIN, LIPID DROPLETS, ADIPOSE TISSUE DEVELOPMENT AND HUMAN OBESITY

Human obesity is, in essence, the accumulation of lipid droplets, which are storage granules of fat. We have uncovered a role for a human disease gene – SEIPIN – in lipid droplet formation. Our recent data suggest that Seipin may regulate the metabolism of fatty acids and phospholipids.

Our current aim is to determine the molecular function of SEIPIN, and how it regulates lipid droplet morphology and adipocyte development. We are also studying other proteins that regulate lipid storage. Students will learn techniques in molecular biology such as CRISPR and lipid analyses.

Selected References

Honours may also be undertaken with the following approved external supervisors located in institutions affiliated with the School of BABS. Students should contact these supervisors directly for information on available projects. Please note that it is UNSW policy that a BABS academic must be assigned as the primary supervisor; the external supervisor will be the designated co-supervisor.

**Dr Till Böcking**  
Single Molecule Science, UNSW School of Medical Sciences  
E till.boecking@unsw.edu.au  
T +612 9385 1179  
Research area  
Mechanisms of molecular motors; imaging of cellular processes; single molecule biophysics.

**A/Professor Antony Cooper**  
Head, Neuroscience Division, Garvan Institute of Medical Research  
E a.cooper@garvan.org.au  
T +612 9295 8238  
Research area  
Discovery of underlying mechanisms and biomarkers of neurodegeneration and Parkinson’s Disease using neurogenomics, cell and molecular approaches on a range of in vitro and in vivo approaches.

**Dr Jennifer Cropley**  
St Vincent’s Clinical School, UNSW Faculty of Medicine  
E j.cropley@unsw.edu.au  
T +612 9295 8619  
Research area  
Epigenetics, environmental epigenetics, epigenetic inheritance.

**Professor Peter Croucher**  
Garvan Institute of Medical Research  
E p.croucher@garvan.org.au  
T +612 9295 8100  
Research area  
Cellular and molecular mechanisms responsible for physiological and pathological regulation of the skeleton.

**A/Professor Sally Dunwoodie**  
Victor Chang Cardiac Research Institute  
E s.dunwoodie@victorchang.edu.au  
T +612 9295 8613  
Research area  
Identifying gene mutations that cause birth defects in humans through whole genome sequencing, bioinformatics, embryology, imaging and CRISPR/TALEN generation of mouse and zebrafish models of disease.

**Dr Dan Hesselson**  
Diabetes and Metabolism Division, Garvan Institute of Medical Research  
E d.hesselson@garvan.org.au  
T +612 9295 8258  
Research area  
Parkinson’s Disease; functional genomics; in vivo drug discovery.

**Dr Lawrence Lee**  
Single Molecule Science, UNSW School of Medical Sciences  
E lawrence.lee@unsw.edu.au  
T +612 9385 8252  
Research area  
Synthetic biology.

**Professor Bill Rawlinson AM**  
Director, Serology & Virology Division, SEALS Microbiology, Prince of Wales Hospital  
E w.rawlinson@unsw.edu.au  
T +612 9382 9113  
Research area  
Molecular biology of viruses, particularly cytomegalovirus, clinical virology, enteroviruses and diabetes, and respiratory viruses.

**Dr Catherine Suter**  
Victor Chang Cardiac Research Institute  
E c.suter@victorchang.edu.au  
T +612 9295 8720  
Research area  
Epigenetic variation and epigenetic inheritance in mammals.

**Professor Seán O’Donoghue**  
BioVis Centre, Garvan Institute of Medical Research  
E s.odonoghue@unsw.edu.au  
T +612 9295 8329  
Research area  
Systems biology, computational biology, bioinformatics.
1 Can I start Honours in Term 3?
Yes, the School of BABS offers Honours intake in all terms (1, 2 and 3).

2 What is included in the overall WAM and stage 3 Science WAM?
Every course completed in stages 1 to 3 is included in the overall WAM. This includes general education courses. Stage 3 Science WAM includes level 3 courses run by the Faculty of Science with the prefix: AVIA, BIOS, BEES, CLIM, GEOS, IEST, MSCI, ENVS, BABS, BIOC, BIOT, MICR, CHEM, COMP, FOOD, MATS, MATH, ANAT, NEUR, PATH, PHAR, PHSL, PSYC, PHYS, VISN or SCIF.

3 I only have one more course left to complete for my program. Can I start Honours and complete my last course at the same time?
No. Students must successfully complete all requirements from stages 1 to 3 of their degree before commencing Honours.

4 I have one more course to complete for my program, but I will be completing this in the summer session before Honours commences in Term 1. Am I still allowed to apply for a Term 1 start?
Yes. Your Honours application will be assessed as normal. If your application is successful, you will be given a conditional offer based on you passing your remaining summer session course.

5 I have met with a potential supervisor and they have agreed to supervise me. Does this mean I am guaranteed acceptance into Honours?
No. Potential supervisors may express their interest in supervising you for Honours and you may include them in your Project Preference List, however only the School can formally accept students into Honours and allocate students to supervisors.

6 Why is there a limit on the number of external supervisors we can nominate in our project preference list?
There are two reasons for this limit:
(a) to ensure that an optimum number of students undertake their Honours project while located within BABS;
(b) to ensure all students have the best possible chance to be allocated a supervisor. External supervisors are restricted to accepting only one student per intake, making placements very competitive.

Please note that for external supervisors, it is UNSW policy that a BABS academic based in the School be assigned as the primary supervisor and will co-supervise the student.

7 Can I request an external supervisor not on the external supervisor list?
No. Students may only nominate approved BABS external supervisors. If you include any external supervisors on your preference list that are not approved, they will be ignored.